A drug that was expected to be approved soon must instead undergo more regulatory scrutiny.
BREAKING NEWS | Mike Segar/Reuters |
F.D.A. Delays Action on Closely Watched Alzheimer's DrugEli Lilly's donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug's safety and efficacy. Read more | | | Get more breaking news in your inbox Sign up to receive emails from The New York Times as soon as important news breaks around the world. Get it in your inbox |
| |
Continue reading the main storyContinue reading the main story |
No comments:
Post a Comment